These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 11459516)

  • 21. Power Analysis and Sample Size Planning in ANCOVA Designs.
    Shieh G
    Psychometrika; 2020 Mar; 85(1):101-120. PubMed ID: 31823115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis of continuous outcomes: Using pseudo IPD created from aggregate data to adjust for baseline imbalance and assess treatment-by-baseline modification.
    Papadimitropoulou K; Stijnen T; Riley RD; Dekkers OM; le Cessie S
    Res Synth Methods; 2020 Nov; 11(6):780-794. PubMed ID: 32643264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statistical issues on the analysis of change in follow-up studies in dental research.
    Blance A; Tu YK; Baelum V; Gilthorpe MS
    Community Dent Oral Epidemiol; 2007 Dec; 35(6):412-20. PubMed ID: 18039282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline corrections in experimental and quasi-experimental clinical trials.
    Overall JE; Ashby B
    Neuropsychopharmacology; 1991 Jun; 4(4):273-81. PubMed ID: 1867736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analyzing pre-post designs using the analysis of covariance models with and without the interaction term in a heterogeneous study population.
    Wan F
    Stat Methods Med Res; 2020 Jan; 29(1):189-204. PubMed ID: 30757963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of statistical models adjusting for baseline in the analysis of parallel-group thorough QT/QTc studies.
    Sun GG; Quan H; Kringle R; Meng Z
    J Biopharm Stat; 2012; 22(3):438-62. PubMed ID: 22416834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A simple sample size formula for analysis of covariance in cluster randomized trials.
    Teerenstra S; Eldridge S; Graff M; de Hoop E; Borm GF
    Stat Med; 2012 Sep; 31(20):2169-78. PubMed ID: 22495809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assurance for clinical trial design with normally distributed outcomes: Eliciting uncertainty about variances.
    Alhussain ZA; Oakley JE
    Pharm Stat; 2020 Nov; 19(6):827-839. PubMed ID: 32537910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of missing data on type 1 error rates in non-inferiority trials.
    Yoo B
    Pharm Stat; 2010; 9(2):87-99. PubMed ID: 19408241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies.
    Kahan BC; Jairath V; Doré CJ; Morris TP
    Trials; 2014 Apr; 15():139. PubMed ID: 24755011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urn models for response-adaptive randomized designs: a simulation study based on a non-adaptive randomized trial.
    Ghiglietti A; Scarale MG; Miceli R; Ieva F; Mariani L; Gavazzi C; Paganoni AM; Edefonti V
    J Biopharm Stat; 2018; 28(6):1203-1215. PubMed ID: 29565749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of different statistical methods analyzing hypoglycemia data using bootstrap simulations.
    Jiang H; Ni X; Huster W; Heilmann C
    J Biopharm Stat; 2015; 25(1):54-65. PubMed ID: 24905704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Robustness and power of analysis of covariance applied to ordinal scaled data as arising in randomized controlled trials.
    Sullivan LM; D'Agostino RB
    Stat Med; 2003 Apr; 22(8):1317-34. PubMed ID: 12687657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
    Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
    Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline adjustments for binary data in repeated cross-sectional cluster randomized trials.
    Nixon RM; Thompson SG
    Stat Med; 2003 Sep; 22(17):2673-92. PubMed ID: 12939779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statistical analysis of two arm randomized pre-post designs with one post-treatment measurement.
    Wan F
    BMC Med Res Methodol; 2021 Jul; 21(1):150. PubMed ID: 34303343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosing fraudulent baseline data in clinical trials.
    Proschan MA; Shaw PA
    PLoS One; 2020; 15(9):e0239121. PubMed ID: 32998158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consequences of handling missing data for treatment response in osteoarthritis: a simulation study.
    Olsen IC; Kvien TK; Uhlig T
    Osteoarthritis Cartilage; 2012 Aug; 20(8):822-8. PubMed ID: 22441031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of the average baseline versus the time-matched baseline in parallel group thorough QT/QTc studies.
    Meng Z; Quan H; Fan L; Kringle R; Sun G
    J Biopharm Stat; 2010 May; 20(3):665-82. PubMed ID: 20358444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reacting to prognostic covariate imbalance in randomised controlled trials.
    Coskinas X; Schou IM; Simes J; Martin A
    Contemp Clin Trials; 2021 Nov; 110():106544. PubMed ID: 34454099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.